Supplementary Figure 1. Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy
figureposted on 14.04.2021, 10:19 by David Stenehjem, Solomon Lubinga, Keith A Betts, Wenxi Tang, Mads Jenkins, Yongqin YuanYongqin Yuan, John Hartman, Sumati Rao, Jenny LamJenny Lam, David WaterhouseDavid Waterhouse
Sankey diagram of treatment patterns during the study time period (August 2018 to December 2019) for patients with tumor PD-L1 expression <1% (A), 1%–49% (B), and ≥50% (C). 1L: first-line; 2L: second-line; 3L: third-line; Nivo: nivolumab; Pembro: pembrolizumab.